JP2024023246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024023246A5 JP2024023246A5 JP2023190321A JP2023190321A JP2024023246A5 JP 2024023246 A5 JP2024023246 A5 JP 2024023246A5 JP 2023190321 A JP2023190321 A JP 2023190321A JP 2023190321 A JP2023190321 A JP 2023190321A JP 2024023246 A5 JP2024023246 A5 JP 2024023246A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharma
- acceptable salt
- ceutically acceptable
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762478382P | 2017-03-29 | 2017-03-29 | |
| US62/478,382 | 2017-03-29 | ||
| US201762607880P | 2017-12-19 | 2017-12-19 | |
| US62/607,880 | 2017-12-19 | ||
| JP2019553899A JP7383483B2 (ja) | 2017-03-29 | 2018-03-29 | 幹細胞を分化し、癌を処置するための作用薬 |
| PCT/US2018/025107 WO2018183654A1 (en) | 2017-03-29 | 2018-03-29 | Agents for differentiating stem cells and treating cancer |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553899A Division JP7383483B2 (ja) | 2017-03-29 | 2018-03-29 | 幹細胞を分化し、癌を処置するための作用薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024023246A JP2024023246A (ja) | 2024-02-21 |
| JP2024023246A5 true JP2024023246A5 (enExample) | 2024-04-26 |
Family
ID=63676977
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553899A Active JP7383483B2 (ja) | 2017-03-29 | 2018-03-29 | 幹細胞を分化し、癌を処置するための作用薬 |
| JP2023190321A Pending JP2024023246A (ja) | 2017-03-29 | 2023-11-07 | 幹細胞を分化し、癌を処置するための作用薬 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553899A Active JP7383483B2 (ja) | 2017-03-29 | 2018-03-29 | 幹細胞を分化し、癌を処置するための作用薬 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20210087143A1 (enExample) |
| EP (1) | EP3600451B1 (enExample) |
| JP (2) | JP7383483B2 (enExample) |
| CN (1) | CN110799652A (enExample) |
| AU (1) | AU2018244449B2 (enExample) |
| CA (1) | CA3058190A1 (enExample) |
| IL (3) | IL302144A (enExample) |
| WO (1) | WO2018183654A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210087143A1 (en) | 2017-03-29 | 2021-03-25 | Minerva Biotechnologies Corporation | Agents for differentiating stem cells and treating cancer |
| WO2019126357A1 (en) * | 2017-12-19 | 2019-06-27 | Minerva Biotechnologies Corporation | Agents for treating cancer and methods for identifying said agents |
| JP2023530664A (ja) * | 2020-06-10 | 2023-07-19 | デリックス セラピューティクス，インク． | 三環系サイコプラストゲンおよびその使用 |
| WO2021263227A2 (en) | 2020-06-26 | 2021-12-30 | Minerva Biotechnologies Corporation | Anti-nme antibody and method of treating cancer or cancer metastasis |
| CN119317447A (zh) | 2022-04-12 | 2025-01-14 | 米纳瓦生物技术公司 | 抗可变muc1*抗体及其用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3153015B2 (ja) * | 1992-09-07 | 2001-04-03 | サントリー株式会社 | ４−（アミノメチル）シクロヘキサンカルボキサミド誘導体 |
| EP0714299B1 (en) | 1993-07-16 | 2002-04-24 | Merck & Co. Inc. | Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists |
| IL141654A0 (en) * | 1998-09-04 | 2002-03-10 | Byk Gulden Lomberg Chem Fab | Pyranose derivatives and pharmaceutical compositions containing the same |
| CA2363169A1 (en) * | 1999-03-03 | 2000-09-08 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| AU778965B2 (en) | 1999-09-14 | 2004-12-23 | Altana Pharma Ag | Tryptase inhibitors |
| TR200402322T4 (tr) | 1999-12-20 | 2004-12-21 | Altana Pharma Ag | Triptaz inhibitörler |
| TW200418835A (en) * | 2003-01-24 | 2004-10-01 | Tanabe Seiyaku Co | A pyrazolopyrimidine compound and a process for preparing the same |
| WO2006060461A1 (en) | 2004-12-03 | 2006-06-08 | Schering Corporation | Substituted piperazines as cb1 antagonists |
| WO2009002607A1 (en) * | 2007-05-01 | 2008-12-31 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identifying transforming and tumor suppressor genes |
| CA2689945A1 (en) * | 2007-06-26 | 2008-12-31 | Astrazeneca Ab | 1-cyanocyclopropyl-derivatives as cathepsin k inhibitors |
| EP2214485B1 (en) | 2007-09-25 | 2016-07-20 | Minerva Biotechnologies Corp. | Methods for treatment of cancer |
| USRE49686E1 (en) | 2008-09-19 | 2023-10-10 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound and use of same |
| EP3524672B1 (en) * | 2010-06-16 | 2025-05-28 | Minerva Biotechnologies Corporation | Reprogramming cancer cells |
| WO2014014050A1 (ja) | 2012-07-19 | 2014-01-23 | 大日本住友製薬株式会社 | １－（シクロアルキルカルボニル）プロリン誘導体 |
| EP2906541B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| EP3038462B1 (en) * | 2013-08-12 | 2023-03-15 | Minerva Biotechnologies Corporation | Method for enhancing tumor growth |
| WO2015107724A1 (ja) | 2014-01-14 | 2015-07-23 | 大日本住友製薬株式会社 | 縮合５－オキサゾリジノン誘導体 |
| KR20210107166A (ko) * | 2014-04-07 | 2021-08-31 | 미네르바 바이오테크놀로지 코포레이션 | 항-ｎｍｅ 항체 |
| EP3352566A4 (en) * | 2015-09-23 | 2019-07-31 | Minerva Biotechnologies Corporation | SCREENING METHOD FOR ACTIVE SUBSTANCES FOR DIFFERENTIATING STEM CELLS |
| US20210087143A1 (en) * | 2017-03-29 | 2021-03-25 | Minerva Biotechnologies Corporation | Agents for differentiating stem cells and treating cancer |
| WO2019126357A1 (en) | 2017-12-19 | 2019-06-27 | Minerva Biotechnologies Corporation | Agents for treating cancer and methods for identifying said agents |
-
2018
- 2018-03-29 US US16/498,640 patent/US20210087143A1/en not_active Abandoned
- 2018-03-29 AU AU2018244449A patent/AU2018244449B2/en active Active
- 2018-03-29 CN CN201880036852.2A patent/CN110799652A/zh active Pending
- 2018-03-29 CA CA3058190A patent/CA3058190A1/en active Pending
- 2018-03-29 EP EP18777506.9A patent/EP3600451B1/en active Active
- 2018-03-29 JP JP2019553899A patent/JP7383483B2/ja active Active
- 2018-03-29 IL IL302144A patent/IL302144A/en unknown
- 2018-03-29 WO PCT/US2018/025107 patent/WO2018183654A1/en not_active Ceased
-
2019
- 2019-09-25 IL IL26966519A patent/IL269665A/en unknown
-
2021
- 2021-10-28 US US17/512,978 patent/US12202799B2/en active Active
-
2022
- 2022-02-22 IL IL290810A patent/IL290810A/en unknown
-
2023
- 2023-11-07 JP JP2023190321A patent/JP2024023246A/ja active Pending
-
2024
- 2024-06-26 US US18/755,447 patent/US20240409515A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024023246A5 (enExample) | ||
| JP2021504443A5 (enExample) | ||
| JP6544545B2 (ja) | Ｔｎａｐ阻害剤としてのスルホンアミド化合物およびその使用 | |
| TWI769182B (zh) | 過氧化物酶體增生劑活化之受體（ppar）促效劑化合物之結晶及鹽形式 | |
| JP5667297B2 (ja) | ヘテロアリールメチルアミド | |
| CN104955456B (zh) | 作为分拣蛋白抑制剂的n-取代的-5-取代的邻氨甲酰苯甲酸 | |
| JP5494482B2 (ja) | トリアゾール誘導体またはその塩 | |
| RU2015143191A (ru) | Дигидропирролопиридиновые ингибиторы бромодоменов | |
| PL208260B1 (pl) | Związki 1,2,4-triazolu, lek zawierający związek oraz zastosowanie związku | |
| JP2017537948A5 (enExample) | ||
| JP2017522346A5 (enExample) | ||
| JP2014525937A5 (enExample) | ||
| JP2007536231A (ja) | サイトカイン阻害剤 | |
| CN109071523A (zh) | 一种脲类化合物、其制备方法及其医药用途 | |
| JP4823903B2 (ja) | ベンズイミダゾール誘導体 | |
| WO2018124000A1 (ja) | ピリミジン誘導体 | |
| JP4829791B2 (ja) | フラザノベンゾイミダゾール | |
| TW200303308A (en) | Novel compounds | |
| AU2012245082A1 (en) | Aromatic amides and uses thereof | |
| JP2020512002A5 (enExample) | ||
| Julémont et al. | Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors | |
| Wu et al. | Discovery and characterization of benzimidazole derivative XY123 as a potent, selective, and orally available RORγ inverse agonist | |
| Czako et al. | Discovery of IACS-9439, a potent, exquisitely selective, and orally bioavailable inhibitor of CSF1R | |
| AU2015207690B2 (en) | Substituted bicyclic heteroaryl compounds as RXR agonists | |
| CN103739550A (zh) | 2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用 |